Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

著者: Susan M. Domchek, Sophie Postel‐Vinay, Seock‐Ah Im, Yeon Hee Park, Jean‐Pierre Delord, Antoîne Italiano, Jérôme Alexandre, Benoît You, Sara Bastian, Matthew Krebs, Ding Wang, Saiama N. Waqar, Mark C. Lanasa, Joon Haeng Rhee, Haiyan Gao, Vidalba Rocher-Ros, Emma V. Jones, Sakshi Gulati, Anna Coenen-Stass, Iwanka Kozarewa, Zhongwu Lai, Helen K. Angell, Laura Opincar, Pia Herbolsheimer, Bella Kaufman - The Lancet 2020 被引用: 459